Tango Therapeutics (TNGX) Non Operating Investment Income (2020 - 2024)
Tango Therapeutics (TNGX) posted quarterly Non Operating Investment Income of -$443000.0 for Q1 2024, down 129.45% year-over-year from $1.5 million in Q2 2023, and down 151.1% quarter-over-quarter from $867000.0 in Q4 2023.
Tango Therapeutics (TNGX) Non Operating Investment Income (2020 - 2024) Analysis & Trends
Tango Therapeutics' Non Operating Investment Income history runs 5 years deep, the most recent figure standing at -$443000.0 for Q1 2024.
- In Q1 2024, Non Operating Investment Income fell 129.45% year-over-year to -$443000.0; the TTM figure through Mar 2024 stood at $1.9 million (up 60.79% YoY), while the FY2025 annual figure was -$112000.0, down 174.67% from the prior year.
- Non Operating Investment Income for Q1 2024 stood at -$443000.0, down from $867000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $1.5 million in Q1 2023, with the low at -$2.6 million in Q1 2022.
- The 5-year median for Non Operating Investment Income is -$9000.0 (2020), against an average of -$17866.7.
- The sharpest annual moves came in 2022 and 2023: Non Operating Investment Income sank 17733.33% in 2022, then jumped 264.24% in 2023.
- Tango Therapeutics' Non Operating Investment Income stood at -$9000.0 in 2020, then tumbled by 8288.89% to -$755000.0 in 2021, then soared by 252.45% to $1.2 million in 2022, then slipped by 24.67% to $867000.0 in 2023, then plunged by 151.1% to -$443000.0 in 2024.
- Business Quant data shows TNGX's Non Operating Investment Income at -$443000.0 in Q1 2024, $867000.0 in Q4 2023, and $836000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | -443,000.00 |
| Mar 31, 2024 | -443,000.00 |
| Dec 31, 2023 | 867,000.00 |
| Dec 31, 2023 | 867,000.00 |
| Sep 30, 2023 | 836,000.00 |
| Sep 30, 2023 | 836,000.00 |
| Jun 30, 2023 | 684,000.00 |
| Jun 30, 2023 | 684,000.00 |
| Mar 31, 2023 | 1.50 Mn |
| Mar 31, 2023 | 1.50 Mn |
| Dec 31, 2022 | 1.15 Mn |
| Dec 31, 2022 | 1.15 Mn |
| Sep 30, 2022 | -509,000.00 |
| Sep 30, 2022 | -509,000.00 |
| Jun 30, 2022 | -937,000.00 |
| Jun 30, 2022 | -937,000.00 |
| Mar 31, 2022 | -2.65 Mn |
| Mar 31, 2022 | -2.65 Mn |
| Dec 31, 2021 | -755,000.00 |
| Dec 31, 2021 | -755,000.00 |